Teva will also report its BRAVO trial later this year. RAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment Avonex.
Market Data 
Markets 
AI
